There are currently 189 clinical trials in Torrance, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Harbor UCLA Medical Center, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance Memorial Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
NCT04553770
Recruiting
This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 expressed at low levels on cancer cells in a targeted way and delivers deruxtecan to kill them. Anastrozole works by decreasing estrogen production and suppressing... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2024
Locations: Torrance Memorial Physician Network / Cancer Care, Torrance, California
Conditions: Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
Register for Updates
Consent for Use of Stored Patient Specimens for Future Testing
NCT00031408
Recruiting
The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other tissues) for future studies that may include genetic testing.
Gender:
ALL
Ages:
All
Trial Updated:
09/20/2024
Locations: Harbor General/UCLA, Torrance, California
Conditions: HIV Infections
Register for Updates
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052
Recruiting
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk... Read More
Gender:
FEMALE
Ages:
Between 35 years and 50 years
Trial Updated:
09/17/2024
Locations: City of Hope South Bay, Torrance, California +1 locations
Conditions: Ovarian Carcinoma
Register for Updates
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
NCT05686239
Recruiting
The goal of this clinical trial is to evaluate if the investigational drug, RL-007, can improve the cognitive performance of subjects with schizophrenia. The main questions the study aims to answer are: 1. Does RL-007 improve subjects performance in a set of cognitive tasks? 2. Which dose of RL-007 (20 mg or 40 mg) has a larger effect on cognitive performance? 3. How well do subjects tolerate RL-007? In the study, subjects will perform the cognitive tasks at the beginning to get familiar with... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
09/13/2024
Locations: Recognify Research Site, Torrance, California
Conditions: Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia
Register for Updates
A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects Undergoing Cataract Extraction
NCT06594185
Recruiting
A study to evaluate the real-world clinical performance of the enVista Aspire and Aspire Toric intraocular lens (IOL) models EA and ETA and to assess surgeon and subject satisfaction
Gender:
ALL
Ages:
22 years and above
Trial Updated:
09/10/2024
Locations: Site 119, Torrance, California
Conditions: Cataract
Register for Updates
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
NCT02138734
Recruiting
This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2024
Locations: Skyline Urology, Torrance, California
Conditions: Non-muscle Invasive Bladder Cancer
Register for Updates
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
NCT05540327
Recruiting
The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and/or systemic lupus erythematosus (SLE) who have completed the 24 week treatment period of Willow study (MS200569_0003 \[NCT05162586\]).
Gender:
ALL
Ages:
Between 18 years and 76 years
Trial Updated:
08/07/2024
Locations: The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California
Conditions: Systemic Lupus Erythematosus
Register for Updates
PD, PK, and Safety of ALTO-203 in Patients With MDD
NCT06391593
Recruiting
The goal of this clinical trial is to determine the pharmacodynamic effects of ALTO-203 in patients with MDD in a randomized, placebo-controlled, single-dose crossover treatment period. Additionally, safety, tolerability, and PK will be assessed in a subsequent randomized placebo-controlled multi-dose parallel-group treatment period of 28 days. Participants will complete subjective response questionnaires and perform cognitive tasks during the single-dose period, in which participants will rece... Read More
Gender:
ALL
Ages:
Between 25 years and 64 years
Trial Updated:
08/05/2024
Locations: Site 4023, Torrance, California
Conditions: Major Depressive Disorder, Anhedonia
Register for Updates
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588
Recruiting
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with HNSCC (Head and Neck Squamous Cell Carcinoma)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/26/2024
Locations: GSK Investigational Site, Torrance, California
Conditions: Neoplasms, Head and Neck
Register for Updates
Study of Lumateperone in the Treatment of Patients With Bipolar Mania
NCT06462612
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/26/2024
Locations: Clinical Site, Torrance, California
Conditions: Bipolar Disorder, Manic
Register for Updates
Long Haul COVID Rehabilitation & Recovery Research Program
NCT05398692
Recruiting
The purpose of the study is to assess the physiologic, immunologic, and mental health effects of a rehabilitation program on patients with Long Haul COVID (LHC).
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/27/2024
Locations: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California
Conditions: Post-Acute COVID-19 Syndrome
Register for Updates
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
NCT05313165
Recruiting
A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.
Gender:
All
Ages:
Between 18 years and 95 years
Trial Updated:
05/31/2024
Locations: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California
Conditions: Critical Limb Ischemia, Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia
Register for Updates